Drug Profile
Disufenton/acetylcysteine
Alternative Names: Disufenton/N-acetylcysteine; HPN-07/NAC; NHPN-1010; NXY-059/NACLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Hough Ear Institute Scientists; Oklahoma Medical Research Foundation
- Developer Hough Ear Institute Scientists; Otologic Pharmaceutics
- Class Benzenesulfonates; Nitrogen oxides; Small molecules; Sulfur amino acids
- Mechanism of Action Free radical inhibitors; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sensorineural hearing loss; Tinnitus; Traumatic brain injuries
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Traumatic-brain-injuries in USA (PO, Capsule)
- 28 Aug 2022 No recent reports of development identified for research development in Tinnitus in USA (PO, Capsule)
- 17 Feb 2020 Disufenton/acetylcysteine is still in early research phase for Tinnitus in USA (PO, Capsule) (Otologic pharmaceutics pipeline, February 2020)